Search icon

GLYPHIC BIOTECHNOLOGIES, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: GLYPHIC BIOTECHNOLOGIES, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 12 Jul 2022 (3 years ago)
Entity Number: 6534739
ZIP code: 10005
County: New York
Place of Formation: Delaware
Foreign Legal Name: GLYPHIC BIOTECHNOLOGIES, INC.
Address: 28 LIBERTY STREET, NEW YORK, NY, United States, 10005

Agent

Name Role Address
C T CORPORATION SYSTEM Agent 28 LIBERTY STREET, NEW YORK, NY, 10005

DOS Process Agent

Name Role Address
c/o C T CORPORATION SYSTEM DOS Process Agent 28 LIBERTY STREET, NEW YORK, NY, United States, 10005

Form 5500 Series

Employer Identification Number (EIN):
862740771
Plan Year:
2023
Number Of Participants:
20
Sponsors Telephone Number:
Plan Year:
2022
Number Of Participants:
0
Sponsors Telephone Number:

Filings

Filing Number Date Filed Type Effective Date
220712001981 2022-07-12 APPLICATION OF AUTHORITY 2022-07-12

USAspending Awards / Contracts

Procurement Instrument Identifier:
HT942524P0042
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
249993.28
Base And Exercised Options Value:
249993.28
Base And All Options Value:
249993.28
Awarding Agency Name:
Department of Defense
Performance Start Date:
2024-04-08
Description:
MEDICAL R AND D PURCHASE ORDER FOR A DHA STTR PHASE I, PROPOSAL NO. H23C-001-0042, TITLED, "DEVELOPMENT OF ANTI-GLYCAN ANTIBODIES AGAINST MULTI-DRUG RESISTANT ESKAPE WOUND PATHOGENS"
Naics Code:
541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Product Or Service Code:
AN11: HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH

USAspending Awards / Financial Assistance

Date:
2023-09-14
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SINGLE-MOLECULE SEQUENCING OF POST-TRANSLATIONAL PROTEIN MODIFICATIONS - SUMMARY PROTEINS ARE RESPONSIBLE FOR MUCH OF THE STRUCTURE AND FUNCTION OF ALL CELLS. SUBTLE MODIFICATIONS OF VARIOUS PRO- TEINS, I.E., POST-TRANSLATIONAL MODIFICATIONS (PTMS), CAN BE MADE BY CELLS TO PROFOUNDLY AFFECT THE FUNCTION OR STRUCTURE OF THE PROTEIN. FOR EXAMPLE, COMMON MODIFICATIONS SUCH AS PHOSPHORYLATION CAN TURN SOME PROTEINS “OFF” OR “ON”, ACETYLATION CAN ALTER CHROMATIN-BINDING PROTEINS TO CHANGE DNA STRUCTURE AND ACTIVITY, AND METHYL- ATION PLAYS A ROLE IN ACTIVATING NUMEROUS ENZYMES INVOLVED IN GENE REGULATION. PARTICULAR AMINO ACID MODIFICATIONS HAVE BEEN IDENTIFIED AT PRECISE RESIDUES ON ONLY SELECT PROTEINS, IN WHICH CASES ANTIBODIES CAN BE GENERATED TO RECOGNIZE THEM WITH HIGH SENSITIVITY AND SPECIFICITY. ALTHOUGH ANALYSIS BY MASS SPECTROMETRY CAN IDENTIFY THE PRESENCE AND OFTEN THE SITE OF SUCH MODIFICATIONS, A LARGE QUANTITY OF SAMPLE IS NEEDED, AND IT IS DIFFICULT OR IMPOSSIBLE TO DEFINE WHETHER MULTIPLE MODIFICATIONS ARE PRESENT ON A SINGLE PROTEIN MOLECULE. THESE APPROACHES DO NOT ALLOW FOR SINGLE-MOLECULE DETECTION OF PTMS ON MULTIPLE RESIDUES. GLYPHIC BIOTECHNOLOGIES WAS FORMED TO COMMERCIALIZE A NOVEL STRATEGY TO SEQUENCE INDIVIDUAL PROTEIN MOLECULES IN THEIR ENTIRETY. THIS PROCESS IS BASED ON LIGATING THE FIRST (N-TERMINAL) AMINO ACID TO A LINKER MOLECULE CALLED CP, WHICH ENABLES ISOLATION AND HIGHLY SENSITIVE IDENTIFICATION OF THE N-TERMINAL AMINO ACID. THE PROCESS IS REPEATED FOR EACH SUBSEQUENT AMINO ACID, YIELDING THE PROTEIN SEQUENCE. THE APPROACH HAS THE POTENTIAL TO SIMULTANEOUSLY SEQUENCE MILLIONS TO BILLIONS OF INDIVIDUAL PROTEIN MOLECULES IN HOURS. DEVELOPING THIS TECHNOLOGY WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENCING FEASIBLE, INEXPENSIVE, AND ROUTINE. THE CURRENT PROPOSAL FOCUSES ON DEVELOPING REAGENTS SPECIFICALLY TO DETECT AMINO ACIDS CONTAINING THREE SPECIFIC PTMS, ALLOWING THEM TO BE SEQUENCED WITH THIS TECHNOLOGY. IN AIM 1, WE WILL GENERATE ANTIBODIES TO RECOGNIZE PTMS LINKED TO CP, ALLOWING US TO DETECT THOSE MODIFIED AMINO ACIDS IN THE SEQUENCING REACTION. IN AIM 2, WE WILL FURTHER OPTIMIZE THE ANTIBODIES AND DEMONSTRATE THE FEASIBILITY OF USING THEM TO SEQUENCE INDIVIDUAL PROTEINS WITH PTMS AMONG A BACKGROUND OF NON-MODIFIED PROTEINS. SUCCESS OF THESE AIMS WILL ENABLE THE PROSPECTIVE GLYPHIC PROTEIN SEQUENCING PLATFORM TO DETECT AND QUANTIFY PTMS IN COMPLEX PROTEIN MIXTURES WITHOUT ANY PRIOR KNOWLEDGE OF THEIR IDENTITY OR EVEN THEIR EXISTENCE. WHEN COMMERCIALIZED, IT WILL ENABLE CLINICAL DIAGNOSIS OF DISEASE BASED ON THE LEVEL OF KNOWN PTMS IN A PATIENT SAMPLE. MOREOVER, IT WILL ALLOW IDENTIFICATION OF UNIQUE PTMS TO DEVELOP ADDITIONAL TESTS FOR AS-YET UNKNOWN BIOMARKERS.
Obligated Amount:
408939.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-09-13
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SINGLE-MOLECULE PROTEIN SEQUENCING BY BARCODING OF N-TERMINAL AMINO ACIDS - SUMMARY PROTEINS ARE RESPONSIBLE FOR MUCH OF THE STRUCTURE AND FUNCTION OF ALL CELLS. SUBTLE CHANGES IN EXPRESSION OF VAR- IOUS PROTEIN FORMS ARE CRITICAL FOR PROPER GROWTH AND DEVELOPMENT, BUT IRREGULARITIES CAN CAUSE DELETERIOUS CELLULAR EFFECTS OR LARGE-SCALE BIOLOGICAL DYSFUNCTION. SEQUENCING SAMPLES WITH BOTH HIGH- AND LOW-ABUNDANCE PROTEINS COULD GREATLY ACCELERATE RESEARCH INTO PROTEIN FUNCTION AND BIOLOGY, BUT THERE IS CURRENTLY NO EFFICIENT AND COST-EFFECTIVE STRATEGY TO SEQUENCE MIXTURES OF UNKNOWN PROTEIN MOLECULES AT SINGLE-AMINO-ACID RESOLUTION. TWO METHODS ARE COMMERCIALLY AVAILABLE FOR PROTEIN SEQUENCING. THE FIRST METHOD, “EDMAN DEGRADATION”, RE- QUIRES PURIFICATION OF THE INDIVIDUAL TARGET PROTEIN. BULK QUANTITIES OF WHOLE PROTEIN OR PURIFIED FRAGMENTS ARE SEQUENCED BY CLEAVING OFF THE FIRST (N-TERMINAL) AMINO ACID AND CHEMICALLY IDENTIFYING IT. THE SECOND METHOD, BASED ON MASS SPECTROMETRY, REQUIRES ENZYMATICALLY DEGRADING A SINGLE PROTEIN OR MIXTURE OF PROTEINS INTO SMALL FRAGMENTS, THEN ANALYZING THE MOLECULAR MASS AND CHARGE OF EACH FRAGMENT. THIS INFORMATION IS COM- PARED TO THAT OF KNOWN PROTEIN SEQUENCES TO INFER THE IDENTITY OF THE INPUT PROTEINS. BOTH OF THESE METHODS REQUIRE ~1 MILLION MOLECULES OF EACH PROTEIN FOR DETECTION. CURRENTLY, EDMAN DEGRADATION CANNOT BE USED ON HETEROGENEOUS PROTEIN MIXTURES, FURTHER LIMITING ITS UTILITY. SINGLE MOLECULE PROTEIN SEQUENCING IS HINDERED BY THE NUMBER AND DIVERSITY OF AMINO ACIDS, AS WELL AS THE IN- TERACTIONS BETWEEN AMINO ACIDS THAT INTERFERE WITH CHEMICAL IDENTIFICATION OF THEIR SIDE CHAINS. IDENTIFYING N- TERMINAL AMINO ACID THAT IS STILL ATTACHED TO THE REST OF THE PROTEIN WILL BE HINDERED BY THE N-1 (AND N-2) AMINO ACIDS, PROPORTIONAL TO THE BULK OF THE SIDE CHAIN. HARSH DENATURATION AGENTS CAN MITIGATE SOME OF THESE ISSUES. HOWEVER, THESE REAGENTS CAN COMPROMISE THE BIOMOLECULE-BASED IDENTIFICATION SYSTEMS THEMSELVES AND DO NOT FULLY REMOVE THE STERIC HINDRANCE, AFFECTING THE ACCESS TO THE N-TERMINAL AMINO ACID. GLYPHIC BIOTECHNOLOGIES HAS DEVELOPED A NOVEL “NEXT-GENERATION” PROTEIN SEQUENCING STRATEGY, IN WHICH DNA BARCODES ASSOCIATE ROUNDS OF CLEAVED N-TERMINAL AMINO ACID WITH A PROTEIN-SPECIFIC BARCODE. EACH OF THE 20 DIFFERENT AMINO ACIDS WILL BE FIRST CLEAVED (CIRCUMVENTING THE STEARIC HINDRANCE OF THE N-1 AMINO ACID) AND THEN CAPTURED BY SPECIFIC ANTIBODIES. EACH AMINO ACID WILL THEN BE ASSOCIATED WITH TWO BARCODES, INDICATING THE (1) ORIGINATING PROTEIN AND (2) SEQUENTIAL POSITION THIS AMINO ACID CAN BE FOUND IN. AFTER NEXT-GENERATION DNA SE- QUENCING OF ALL CONJUGATED BARCODES, THIS INFORMATION CAN BE DECONVOLUTED – PLACING EACH AMINO ACID INTO THE CORRECT POSITION WITHIN THE CORRECT PROTEIN. THIS APPROACH HAS THE POTENTIAL TO BE SCALED TO SEQUENCE MILLIONS TO BILLIONS OF SINGLE MOLECULES SIMULTANEOUSLY IN HOURS. DEVELOPING THIS TECHNOLOGY WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENC- ING FEASIBLE, INEXPENSIVE, AND ROUTINE.
Obligated Amount:
358981.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-08-15
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SINGLE-MOLECULE PROTEIN SEQUENCING BY DETECTION AND IDENTIFICATION OF N-TERMINAL AMINO ACIDS - SUMMARY - SUBTLE CHANGES IN PROTEIN EXPRESSION ARE CRITICAL FOR PROPER GROWTH AND DEVELOPMENT, BUT IRREGU- LARITIES CAN CAUSE DELETERIOUS CELLULAR EFFECTS OR LARGE-SCALE BIOLOGICAL DYSFUNCTION. SEQUENCING SAMPLES WITH COMPLEX MIXTURES OF PROTEINS COULD GREATLY ACCELERATE RESEARCH INTO PROTEIN FUNCTION AND BIOLOGY, BUT THERE IS CURRENTLY NO EFFICIENT AND COST-EFFECTIVE STRATEGY FOR PROTEIN SEQUENCING AT SINGLE-AMINO-ACID RESOLUTION. TWO METHODS ARE COMMERCIALLY AVAILABLE FOR PROTEIN SEQUENCING. IN THE FIRST, “EDMAN DEGRADATION”, BULK QUANTI- TIES OF WHOLE PROTEIN OR PURIFIED FRAGMENTS ARE SEQUENCED BY CLEAVING THE FIRST (N-TERMINAL) AMINO ACID AND CHEM- ICALLY IDENTIFYING IT. IN THE SECOND METHOD, BASED ON MASS SPECTROMETRY, A SINGLE PROTEIN OR MIXTURE OF PROTEINS IS FRAGMENTED, AND THE MOLECULAR MASS AND CHARGE OF EACH FRAGMENT ARE ANALYZED. THIS INFORMATION IS COMPARED KNOWN PROTEIN SEQUENCES TO INFER THE IDENTITY OF THE INPUT PROTEINS. BOTH OF THESE METHODS REQUIRE ~1 MILLION MOLECULES OF EACH PROTEIN, AND EDMAN DEGRADATION CANNOT CURRENTLY BE USED ON HETEROGENOUS PROTEIN MIXTURES. EXISTING APPROACHES FOR SINGLE MOLECULE PROTEIN SEQUENCING ARE HINDERED BY THE NUMBER AND DIVERSITY OF AMINO ACIDS, AS WELL AS THE INTERACTIONS BETWEEN AMINO ACIDS THAT INTERFERE WITH CHEMICAL IDENTIFICATION OF THEIR SIDE CHAINS. HARSH DENATURATION AGENTS CAN MITIGATE SOME ISSUES, BUT THEY CAN COMPROMISE THE IDENTIFICATION SYSTEMS THEMSELVES. IN ADDITION, DENATURATION AGENTS ONLY REMOVE SOME OF THE INTRAMOLECULAR INTERACTIONS OF PROTEINS. GLYPHIC BIOTECHNOLOGIES IS DEVELOPING A NOVEL STRATEGY TO SEQUENCE INDIVIDUAL PROTEIN MOLECULES IN THEIR ENTIRETY FROM A HETEROGENEOUS SAMPLE. THIS PROCESS IS BASED ON LIGATING THE N-TERMINAL AMINO ACID TO A CLEAVABLE CHEM- ICAL LINKER, WHICH SUBSEQUENTLY TETHERS IT LOCALLY TO THE SURFACE. CLEAVAGE OF THE LINKER REMOVES THE N-TERMINAL AMINO ACID FROM THE PROTEIN FOR HIGHLY SENSITIVE IDENTIFICATION WITH NO INTERFERENCE FROM PROTEIN STRUCTURE OR ADJA- CENT AMINO ACIDS. THE PROCESS IS REPEATED FOR EACH SUBSEQUENT AMINO ACID, YIELDING THE PROTEIN SEQUENCE. THE APPROACH MAY SIMULTANEOUSLY SEQUENCE MILLIONS TO BILLIONS OF INDIVIDUAL PROTEIN MOLECULES IN HOURS, WHICH WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENCING FEASIBLE, INEXPENSIVE, AND ROUTINE. THE CURRENT PROPOSAL FOCUSES ON DEVELOPING REAGENTS SPECIFICALLY TO DETECT THE N-TERMINAL AMINO ACID OF PROTEINS, ALLOWING AMINO ACIDS TO BE DIGITALLY IDENTIFIED VIA THIS N-TERMINAL ISOLATION STRATEGY. IN AIM 1 WE WILL GENERATE ANTIBODIES TO RECOGNIZE AT LEAST 10 DIFFERENT ISOLATED AMINO ACIDS – ENOUGH TO IDENTIFY ~90% OF THE PROTEOME AFTER 10 SEQUENCING ROUNDS. IN AIM 2 WE WILL FURTHER OPTIMIZE THE ANTIBODIES AND DEMONSTRATE THE FEASIBILITY OF USING THEM TO SEQUENCE INDIVIDUAL PROTEINS AMONG A BACKGROUND OF NON-MODIFIED PROTEINS. SUCCESS OF THESE AIMS WILL ENABLE THE GLYPHIC PROTEIN SEQUENCING PLATFORM TO DETECT, QUANTIFY, AND SEQUENCE SINGLE PROTEINS IN COMPLEX PROTEIN MIXTURES IN AN UNBIASED FASHION - WITHOUT ANY PRIOR KNOWLEDGE OF THEIR IDENTITY OR EVEN THEIR EXISTENCE. WHEN COMMERCIALIZED, IT WILL ENABLE CLINICAL DIAGNOSIS OF DISEASE BASED ON THE PROTEINS PRESENT IN A PATIENT SAMPLE AND ALLOW IDENTIFICATION OF UNIQUE PROTEINS TO FOR AS-YET UNKNOWN BIOMARKERS.
Obligated Amount:
390584.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-02-28
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SINGLE-MOLECULE PROTEIN SEQUENCING BY ITERATIVE ISOLATION AND IDENTIFICATION OF N-TERMINAL AMINO ACIDS - SUMMARY PROTEINS ARE RESPONSIBLE FOR MUCH OF THE STRUCTURE AND FUNCTION OF ALL CELLS. SUBTLE CHANGES IN EXPRESSION OF VARIOUS PROTEIN FORMS ARE CRITICAL FOR PROPER GROWTH AND DEVELOPMENT, BUT IRREGULARITIES CAN CAUSE DELETERIOUS CELLULAR EFFECTS OR LARGE-SCALE BIOLOGICAL DYSFUNCTION. PROTEINS CONSIST OF CHAINS OF AMINO ACIDS, WHICH ULTIMATELY DETERMINE THE THREE-DIMENSIONAL STRUCTURE AND FUNCTIONALITY OF THE PROTEIN. AS SUCH, THE ABILITY TO GATHER THE ENTIRE AMINO ACID SEQUENCE OF LOW ABUNDANCE PROTEINS CAN GREATLY ACCELERATE RESEARCH INTO PROTEIN FUNCTION AND BIOL- OGY. HOWEVER, IN STARK CONTRAST TO THE RELATIVE SUCCESS OF DNA SEQUENCING TECHNOLOGIES, THERE IS CURRENTLY NO EFFICIENT AND COST-EFFECTIVE STRATEGY TO SEQUENCE SINGLE PROTEIN MOLECULES AT SINGLE-AMINO-ACID RESOLUTION. TWO METHODS ARE COMMERCIALLY AVAILABLE FOR PROTEIN SEQUENCING. THE FIRST METHOD, “EDMAN DEGRADATION”, RE- QUIRES PURIFICATION OF THE TARGET PROTEIN. BULK QUANTITIES OF WHOLE PROTEIN OR PURIFIED FRAGMENTS ARE SEQUENCED BY CLEAVING OFF THE FIRST (N-TERMINAL) AMINO ACID AND CHEMICALLY IDENTIFYING IT. THE SECOND METHOD, BASED ON MASS SPECTROMETRY, REQUIRES ENZYMATICALLY DEGRADING A SINGLE PROTEIN OR MIXTURE OF PROTEINS INTO SMALL FRAGMENTS, THEN ANALYZING THE MOLECULAR MASS AND CHARGE OF EACH FRAGMENT. THIS INFORMATION IS COMPARED TO THAT OF KNOWN PROTEIN SEQUENCES TO INFER THE IDENTITY OF THE INPUT PROTEINS. BOTH OF THESE COMMERCIALLY AVAILABLE METHODS SUFFER FROM LOW SENSITIVITY, REQUIRING ~1 MILLION MOLECULES OF EACH PROTEIN FOR DETECTION. EDMAN DEGRADATION CANNOT CURRENTLY BE USED IN HETEROGENOUS PROTEIN MIXTURES, FURTHER LIMITING ITS UTILITY. CRITICAL HURDLES IN SINGLE MOLECULE PROTEIN SEQUENCING ARE THE NUMBER AND DIVERSITY OF AMINO ACIDS, AS WELL AS THE INTERACTIONS BETWEEN AMINO ACIDS THAT INTERFERE WITH REAGENTS THAT CAN IDENTIFY AMINO ACIDS BY THEIR CHEMICAL SIDE CHAINS. CURRENT APPROACHES BEING DEVELOPED FOR SINGLE-MOLECULE PROTEIN SEQUENCING COULD AVOID SOME OF THESE ISSUES BY EMPLOYING HARSH DENATURATION AGENTS, BUT THESE CAN COMPROMISE THE IDENTIFICATION SYSTEMS THEMSELVES. IN ADDITION, DENATURATION AGENTS ONLY REMOVE SOME OF THE INTRAMOLECULAR INTERACTIONS OF PROTEINS. GLYPHIC BIOTECHNOLOGIES HAS DEVELOPED A NOVEL STRATEGY TO ITERATIVELY IDENTIFY THE FIRST (N-TERMINAL) AMINO ACID BY ISOLATING IT FROM THE REMAINDER OF THE PROTEIN, USING A LINKER MOLECULE CALLED CLICKP. AFTER BINDING THE PROTEIN TO A SOLID SURFACE, CLICKP ENABLES SINGLE MOLECULE PROTEIN SEQUENCING BY A REITERATIVE METHOD OF PHYSICALLY ISO- LATING THE TERMINAL AMINO ACID, THEN ENABLING ITS IDENTIFICATION AT HIGH SPECIFICITY AND SINGLE-MOLECULE SENSITIVITY. THE APPROACH HAS THE POTENTIAL TO BE SCALED TO SEQUENCE MILLIONS TO BILLIONS OF SINGLE MOLECULES SIMULTANEOUSLY IN HOURS. DEVELOPING THIS TECHNOLOGY WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENC- ING FEASIBLE, INEXPENSIVE, AND ROUTINE.
Obligated Amount:
409295.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 21 Mar 2025

Sources: New York Secretary of State